The effect of 8 or 5 years of denosumab treatment in ... - FLORE

Furthermore, given that osteoporosis is a chronic condition, and prolonged administration of bisphosphonates has raised concerns about rare but serious adverse ...







Denosumab: Prolia®; Jubbonti®; Xgeva®; Wyost®
Patients should be encouraged to continue denosumab therapy long term. If discontinuation does occur, appropriate steps must be taken to prevent the rapid bone.
Denosumab: A novel antiresorptive drug for osteoporosis
Where treatment for osteoporosis is required beyond 5 years of bisphosphonate therapy, options other than bisphosphonates, such as denosumab, may be considered, ...
denosumab (Prolia) - Blue Shield of California
Rare side effects and risks related to the drug, such as osteonecrosis of the jaw (ONJ), atypical femoral fractures (AFF), and rebound effect should always be.



Autres Cours:

Aetna Better Health®